Chick-Fil-A backtracks from its no-antibiotics-in-chicken pledge, blames projected supply shortages
ATLANTA (AP) — The fast-food chain Chick-Fil-A backtracked from its decade-old “no antibiotics ever” pledge intended to help prevent human antibiotic resistance linked to the rampant use of the drugs in livestock production.
Instead, the company said in a statement that it will embrace a standard known as “no antibiotics important to human medicine,” often abbreviated as NAIHM, which entails the avoidance of medications commonly used to treat people and limits the use of animal antibiotics to cases of actual animal illness.
Livestock producers have long used antibiotics to boost rapid weight gain in animals such as chickens, pigs, cows and sheep, improving the profitability of their businesses. Over the past decade, however, many nations, including the United States, have begun to restrict the practice as evidence mounted that it was contributing to drug resistance and reducing the effectiveness of antibiotics against disease in humans.
Chick-Fil-A said it will begin shifting to the new policy in the spring of 2024. A company spokesman added that the move reflects company concerns about its ability to acquire sufficient supplies of antibiotic-free chicken. One of the poultry industry’s largest companies, Tyson Foods, said last year that it was reintroducing some antibiotics to its chicken production and removing its “No Antibiotics Ever” package labeling. It began to eliminate antibiotics from some of its poultry production in 2015.
In a May 2023 video featured on the Tyson Foods YouTube channel, Tyson’s senior director of animal welfare, Karen Christensen, described the shift as “based on scientific research and industry learnings.” She noted that Tyson planned to begin using antibiotics known as ionophores, which don’t play a role in human medicine, to “improve the overall health and welfare of the birds in our care.” Ionophores have long been used to promote growth in livestock.
Disclaimer: The copyright of this article belongs to the original author. Reposting this article is solely for the purpose of information dissemination and does not constitute any investment advice. If there is any infringement, please contact us immediately. We will make corrections or deletions as necessary. Thank you.
